Neosoma Brain Mets
AI-powered automated lesion tracking and analysis for brain metastases
Software · Cloud SaaSCompany source
Company profile
About Neosoma
Neosoma is a medical technology company that has developed a cloud-based AI platform purpose-built for multidisciplinary neuro-oncology teams. The company's FDA-cleared software automates and simplifies critical tasks in brain tumor assessment, including lesion mapping, volumetric measurement, longitudinal tracking, and GTV contour generation for treatment planning. Neosoma's platform maps intratumoral lesion compartments at the voxel level with precision and consistency, automatically quantifies total tumor burden and lesion counts at every timepoint, and tracks lesions across all patient studies. The technology is currently cleared for gliomas and brain metastases, integrating seamlessly with PACS systems and radiation treatment planning software. The platform is SOC2 Type II certified, HIPAA compliant, and designed to serve neurosurgeons, radiation oncologists, neuroradiologists, and medical oncologists. Neosoma's mission is to improve patient outcomes by delivering novel insights to the entire care team, reducing segmentation time by over 50% while maintaining clinical accuracy comparable to expert manual contouring. The solution is reimbursable through Category 3 CPT codes and has been adopted by leading clinical sites including Hackensack Meridian Health and Inselspital.
Company description Neosoma official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Neosoma?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Brain metastases
- Glioblastoma
- Gliomas
- High-grade gliomas
Who it serves
- Academic Medical Centers
- Health Systems
- Neurosurgery Departments
- Radiation Oncology Centers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Eclipse, Gamma Plan, MIM, Nuance Precision Imaging Network, PACS, Stealth.
Geographic context
MarketsSwitzerland · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for Neosoma HGG (September 2022). Strategic partnership with Hackensack Meridian Health (February 2023). Expanded collaboration with Inselspital (November 2025). Renewed SOC2 Type II certification (August 2024). Innolitics case study published (February 2026).
Partnerships
Recorded partners
- Calyx
- Hackensack Meridian Health
- Innolitics
- Inselspital
- Nuance Communications
- University of Bern
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Neosoma Cloud Platform
Integrated cloud platform for multidisciplinary neuro-oncology teams
Platform · Cloud SaaSCompany source
Neosoma Glioma
AI-powered automated lesion analysis and contouring for gliomas
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.Scientific data · Jan 27, 2026
Author Correction: Federated learning enables big data for rare cancer boundary detection.Nature communications · Jan 26, 2023
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics.Neuro-oncology advances · Jan 1, 2023
Federated learning enables big data for rare cancer boundary detection.Nature communications · Dec 5, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Neosoma Brain MetsK252922 · 510k · Dec 17, 2025
NS-HGlioK221738 · 510k · Sep 27, 2022
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Segmentation time reduction
Pre-operative: 210.5s to 15s, post-operative: 179s to 15s (P<0.0001)
Contouring time reduction
Over 50% reduction in RT workflow contouring time
Clinical accuracy
Geometric performance comparable to expert variability and dosimetric equivalence to consensus contours
Hackensack Meridian Health
Strategic partnership for innovation in brain tumor treatment and research
Inselspital and University of Bern
Evaluation of automated GTV segmentation for glioblastoma radiotherapy
Over 50% reduction in contouring time with geometric performance comparable to expert variability and dosimetric equivalence to consensus contours
Mount Sinai Icahn School of Medicine
Objective assessment of brain tumor MRI results and treatment response decisions
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Ken Kolodziej
Co-Founder and Chief Executive Officer
Michael Hill
Chief Technology Officer
Charlotte Anderson
Controller
Amith Kamath
Radiation Oncology Engineering
Katherine Kacena
Biostatistics
Josh Hess
Front-End Engineer
Michael Müller
Senior AI Engineer
John Liedtky
Clinical Commercialization
06 · Company updates
Updates from Neosoma
Recent articles published on Neosoma's official website.
Innolitics Publishes Case Study Highlighting Neosoma Collaboration
Read on NeosomaNeosoma GmbH and Inselspital Announce Collaboration
Read on NeosomaNeosoma To Present At TCA Venture Group Signal Event
Read on NeosomaNeosoma Receives Renewed SOC2 Type II Certification
Read on NeosomaNeosoma Receives SOC 2 Type II Certification
Read on Neosoma07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.